Navigation Links
QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
Date:6/7/2013

ader platform targeted for placements to select customer groups in 2013.

Since sequencing of entire human genomes requires considerable resources and time, users of NGS technology in clinical research and diagnostics often prefer to perform targeted sequencing of clinically relevant genes based on focused gene panels of interest. This expanding portfolio of products addresses the urgent needs of customers to efficiently generate relevant NGS data by providing fast turnaround time, low DNA input requirements and quality control standards, all of which result in more cost-effective, accurate and reproducible results from each sequencing run.

QIAGEN's current offering includes eight focused and curated NGS gene panels for a range of cancers -

breast, colon, liver, lung, ovarian, prostate, gastric and blood - and each covering approximately 20 different genes of interest. QIAGEN also already offers a comprehensive cancer panel covering 124 different genes. The panels being launched will focus on various cancers as well as new disease areas, and QIAGEN intends to continuously expand this portfolio with new panel offerings.

In addition to the workflow benefits of these panels, QIAGEN is integrating access to the cloud-based Variant Analysis™ software acquired with Ingenuity Systems in early 2013 to its gene panels, enabling customers to rapidly translate raw sequencing data into actionable results. This biological interpretation solution enables customers to rapidly identify and prioritize genetic variants, accessing the most current and advanced interpretations of genomic data.

One of the early users of QIAGEN's GeneRead DNAseq gene panels is Prof. Dr. Reinhard Büttner, head of the Institute for Pathology at the University of Cologne, a leading European institution for NGS-based lung cancer testing that has been evaluating QIAGEN's gene panels for lung cancer and leukemia
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
2. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
3. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
4. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
5. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
6. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
7. For Multiple Sclerosis Treatment, Prescriber Base for Genzymes Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
8. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
9. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
10. Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
11. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors ... BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, ... announced financial results for its first fiscal quarter ... Quarter Highlights and Recent Developments: ... in improving its cost structure, driven by lower ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Array BioPharma ... for the fourth quarter and full year of ... Ron Squarer, Chief Executive Officer of Array, noted, ... Phase 3, are on track for regulatory submissions ... in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... 04, 2007 /PRNewswire/ -- Novagali Pharma, an,emerging ... positive results from the Phase III,clinical study ... (VKC). In this orphan disease, it was ... improved in patients,receiving Vekacia(R). Furthermore, the tolerability ...
... Phase III study of ERBITUX with,chemotherapy in ... primary endpoint of improving overall survival --, ... ImClone,Systems Incorporated and Bristol-Myers Squibb Company announced,today ... of ERBITUX(R) (Cetuximab),combined with platinum-based chemotherapy met ...
Cached Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 9
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... as one of 20 finalists for America’s Favorite Veterinarian. The contest is put ... by a judging committee from 500 nominees. Nominees were evaluated on community involvement, ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of higher learning, announced today that its RN to BSN and Master ... been awarded full accreditation through June 2020 from the Commission on Collegiate ...
(Date:8/4/2015)... ... 04, 2015 , ... Continuing Education Company (CEC) ... interaction simulation session entitled "NOACS: What the Evidence Shows in Managing AFib, ... Inc. and EDUmotion US LLC. , This special activity was recently presented during ...
(Date:8/4/2015)... ... 2015 , ... IN AMERICA and the program's host, James ... affects millions of Americans every single year. To help people obtain a better ... the latest segment produced with the assistance of several top medical professionals. ...
(Date:8/4/2015)... ... 04, 2015 , ... Healthcare IT News (HITN), ... in healthcare and technology markets, today announced significant spikes in website traffic and ... Health Record (EHR) decision. The DOD related numbers solidify HITN’s status as the ...
Breaking Medicine News(10 mins):Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2
... study shows that arthritis in the knee is linked to ... than the other. Whether or not leg length differential is ... findings may allow people to take preventive measures before the ... for treatment may be possible, says Derek Cooke, Queen,s University ...
... ... consumer E-commerce site offering wholesale prices on over 15.000 organic and natural items. Using the ... club becomes the first organic and natural online retailer to do this with a large ... (PRWEB) March ...
... medication cuts cancer risk , WEDNESDAY, March 31 (HealthDay News) ... to fight the problems of an enlarged prostate gland can ... a debate that started with an earlier study of a ... April 1 issue of the New England Journal of ...
... dying needed someone else to make decisions, research finds , ... directives, such as a living will or a durable power ... of medical care that they,ve requested as they near the ... study also found that 30 percent of people required another ...
... part or all of their stomach removed, the hormone ... according to a new study in Gastroenterology , ... Institute. "It is our obligation to invent novel ... study provides convincing data for the beneficial effects of ...
... A new study conducted by Italian researchers, in collaboration ... that biofeedback is more effective than two other treatments for ... "The importance of this work is that chronic rectal ... treat nothing seems to work for more than a ...
Cached Medicine News:Health News:Organic Wholesale Club Brings Wholesale Club Concept to Large Organic and Natural E-commerce Site 2Health News:Study Revives Debate on Prostate Drug 2Health News:Study Revives Debate on Prostate Drug 3Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 2Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 3Health News:Promising hormone may help reduce malnutrition in gastric cancer patients 2Health News:Biofeedback more effective than EGS and massage for chronic rectal pain 2
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
For the quantitative in vitro determination of Total Protein in serum and plasma...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: